Navigation Links
ViroPharma to Participate in Two December Healthcare Investor Conferences
Date:12/5/2011

EXTON, Pa., Dec. 5, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Robert Doody, assistant director of investor relations of ViroPharma, will present at the 2011 Deutsche Bank BioFEST Conference at 8:35 A.M. ET on Tuesday, December 6, 2011.  The conference is being held at the Four Seasons Hotel in Boston.

Charles Rowland, vice president and chief financial officer, of ViroPharma, will present at the Oppenheimer 22nd Annual Healthcare Conference at 4:30 P.M. ET on Tuesday, December 13, 2011.  The conference is being held at the Waldorf Astoria Hotel in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business.

 


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... and NEWARK, Del. , March 29, ... regenerative medicine company, and W. L. Gore ... today announced a collaborative research agreement whereby the two ... therapy delivery device technologies that provide protection from immune ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
(Date:3/29/2017)... -- The Global Microfluidic Chips Market by Manufacturers, Countries, ... comprehensive study on the existing state of the global Microfluidic Chips ... Europe and Asia-Pacific , ... Africa . ... Browse 172 Tables and Figures, 13 Major Company Profiles, ...
(Date:3/28/2017)... ... , ... Franz Inc ., the leading supplier of Semantic Graph Database ... ‘Champion’ by Bloor Research in its recent Graph Database Market Update report. ... to Gruff, it was rated as the easiest product to use.” – Bloor Research ...
(Date:3/28/2017)... 2017 Summary This report provides ... and its partnering interests and activities since 2010. Description ... in-depth insight into the partnering activity of one of the ... reports are prepared upon purchase to ensure inclusion of the ... The report will be delivered in PDF format within 1 ...
Breaking Biology Technology:
(Date:3/7/2017)... CITY , March 7, 2017   HireVue ... help top global companies identify the best talent, faster, ... as Chief Sales Officer (CSO) and Diana Kucer ... appointments round out a seasoned executive team poised to drive ... beyond, building on a year of record bookings in ...
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
Breaking Biology News(10 mins):